*From the Authors*:

We thank Ning and colleagues for their suggestions aimed at exploring whether RVX-208 therapy in pulmonary arterial hypertension (PAH) is associated with enhanced concentration of plasmatic high-density lipoprotein cholesterol (HDL-C), whether these anticipated changes contribute to the improvement of vascular remodeling and pulmonary hemodynamics seen in our models, whether the circulating HDL-C level can be used as a clinical biomarker in future PAH clinical studies, and whether our findings could be extrapolated to other forms of pulmonary hypertension (PH).

As mentioned by Ning and colleagues, reduced HDL-C levels characterize patients with PAH and are associated with worse prognosis ([@bib1]). Interestingly, RVX-208 (apabetalone) was originally developed as a lipid-modifying agent, inducing hepatic synthesis of apoA-I (apolipoprotein A-I) and enhancing the cholesterol efflux capacity of HDL. However, early studies evaluating the administration of apabetalone in patients with coronary artery disease (CAD) revealed modest elevation of apoA-I and HDL-C ([@bib2]), suggesting that apabetalone may have actions beyond those on lipoproteins. As a result of their ability to bind acetylated histone tails, as well as to interact and modulate the activity of many regulators of transcription, members of the bromodomain and extra-terminal domain protein family such as BRD4 (bromodomain-containing protein 4) are implicated in many cellular processes and cell growth. As such, their inhibition is expected to exert pleiotropic actions, concomitantly affecting different aspects of PAH pathophysiology.

We consistently documented previously that BRD4 inhibition reversed the oncogenic NFAT, Bcl-2, and survivin upregulation, restoring the PAH--pulmonary artery smooth muscle cell proliferation/apoptosis imbalance and improving pulmonary hemodynamics in PH rat models ([@bib3]). We also documented that BRD4 expression was increased in coronary arteries of patients with PAH, contributing to vascular remodeling and the development of concomitant CAD ([@bib4]). Interestingly, BRD4 is also known to regulate RUNX2, which accounts for calcification lesions seen in PAH ([@bib5], [@bib6]). Of note, the effects of BRD4 inhibition on PAH and CAD were at least in part mediated through its effects on metabolism and inflammation ([@bib4], [@bib7]). As proposed by Ning and colleagues, whether these findings could be extrapolated to other types of PH characterized by inflammatory and metabolic disturbances such as group 2 PH occurring in the setting of a metabolic syndrome ([@bib8]) certainly represents a research priority, given the significant unmet medical needs for these patients.

Obviously, the enhanced HDL-C levels after RVX-208 treatment may also have contributed by itself to the structural and hemodynamic improvements reported in our PAH models ([@bib4], [@bib7]). Consistent with the pleiotropic effects described here, however, the recent pooled analysis of clinical trial phase 2 studies in patients with CAD confirmed that apabetalone reduced the incidence of major adverse cardiovascular events, despite marginal effects on their lipid profile ([@bib2]). Of interest, exploratory analyses suggested that this reduction in major adverse cardiovascular events was most predominantly observed in patients with low HDL-C, elevated inflammation levels, or diabetes at the baseline. As HDL-C positively correlates with systemic inflammatory markers (IL-1b, IL-6, MCP-1 \[monocyte chemoattractant protein-1\], and TNFα \[tumor necrosis factor α\]), apabetalone did not translate either to regression of coronary atherosclerosis volume in patients with CAD or to changes in blood glucose and had only a marginal benefit on inflammation levels ([@bib2]). The exact mechanisms by which apabetalone prevented major adverse cardiovascular events remains elusive. Accordingly, in addition to accumulating mechanistic insights, whether baseline alterations in DNA repair pathways, procalcification processes, inflammation and metabolic defects, or changes upon treatment identify potential biomarkers predicting or paralleling response to BRD4 inhibition, allowing the molecular stratification of patients with PAH and precision medicine will be explored in our ongoing clinical study (APPRoAcH; clinical trial registered with [www.clinicaltrials.gov](http://www.clinicaltrials.gov) \[NCT 03655704\]), evaluating apabetalone in PAH.
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